← All indications
Anemia, Hemolytic
A condition of inadequate circulating red blood cells (ANEMIA) or insufficient HEMOGLOBIN due to premature destruction of red blood cells (ERYTHROCYTES).
Subtype terms (5)
More specific conditions that are subtypes of Anemia, Hemolytic in the MeSH hierarchy.
- Anemia, Hemolytic, Autoimmune
53 drugs (31 approved, 22 experimental)
- Anemia, Hemolytic, Congenital
4 drugs approved
- Favism
1 drug approved
- Hemoglobinuria, Paroxysmal
55 drugs (30 approved, 25 experimental)
- Hemolytic-Uremic Syndrome
7 drugs (6 approved, 1 experimental)
Drugs by status
Approved for this indication (5)
Phase 4 trials (1)
Phase 2 trials (5)
Phase 1 trials (6)
Other trials (1)
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (8)
Organization Involved with Phase 2 Indications (29)
- Incyte
- Takeda
- Sanofi
- Novartis
- Alexion
- Apellis Pharmaceuticals, Inc.
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Helse Fonna
- University of Pennsylvania
- German CLL Study Group
- Johns Hopkins University
- University of Milan
- University of Oslo
- University of Bordeaux
- Mayo Clinic
- Columbia University
- University of Cologne
- University of Turku
- University of Udine
- Food and Drug Administration
- Annexon
- City of Hope National Medical Center
- Bankura Sammilani Medical College
- Haugesund Hospital
- Assistance Publique - Hôpitaux de Paris
- Kezar Life Sciences, Inc.
- Immunovant Sciences GmbH
- Association of Oncological Hematologists
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (1)